MPI- Molecular Cell Biology and Genetics, DE


Marc Bickle obtained his PhD at the Biozentrum in Basel, Switzerland, studying the immunosuppressive drug Rapamycin. He then went to the LMB in Cambridge, UK, to study the genetics of behavior in C. elegans. He then participated in the creation of Aptanomics, a drug discovery Biotech in Lyon, France. He is currently heading the Technology Development Studio at the MPG-MPI in Dresden, Germany, performing functional genomic and chemical screens.

Speaker at
1 - 4 July 2018, Ghent, Belgium